BioCentury
ARTICLE | Company News

Capricor and Cedars-Sinai expand cardiosphere deal

January 19, 2018 7:58 PM UTC

Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights to develop and commercialize cardiosphere-derived cells (CDC) and CDC-derived extracellular vesicles, including exosomes, by adding seven new patent applications to a 2014 partnership. The new patent applications extend Capricor's exclusive license to the technologies to include indications in Duchenne muscular dystrophy (DMD), ventricular tachyarrhythmia, cancer and age-related diseases.

Previously, Capricor received exclusive worldwide rights from Cedars-Sinai to the technologies from Cedars-Sinai for an undisclosed license fee. The medical center is also eligible for single-digit royalties on sales and a single-digit percentage of any sublicense agreements (see BioCentury, May 19, 2014). ...